47,580 BioLife Solutions, Inc. $BLFS Shares Sold by Conestoga Capital Advisors LLC

Conestoga Capital Advisors LLC reduced its stake in BioLife Solutions, Inc. (NASDAQ:BLFS) by 39.1% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 74,072 shares of the medical equipment provider’s stock after selling 47,580 shares during the period. Conestoga Capital Advisors LLC owned 0.15% of BioLife Solutions worth $2,878,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the stock. Oregon Public Employees Retirement Fund boosted its holdings in BioLife Solutions by 7.8% during the third quarter. Oregon Public Employees Retirement Fund now owns 9,685 shares of the medical equipment provider’s stock worth $376,000 after buying an additional 700 shares during the last quarter. ProShare Advisors LLC acquired a new position in shares of BioLife Solutions during the 3rd quarter worth about $683,000. Transmarket Holdings LP bought a new stake in shares of BioLife Solutions in the 3rd quarter valued at about $5,366,000. Yousif Capital Management LLC increased its stake in shares of BioLife Solutions by 4.9% in the 3rd quarter. Yousif Capital Management LLC now owns 11,097 shares of the medical equipment provider’s stock valued at $431,000 after acquiring an additional 520 shares during the last quarter. Finally, Kings Path Partners LLC bought a new stake in shares of BioLife Solutions in the 3rd quarter valued at about $644,000. 93.24% of the stock is owned by institutional investors and hedge funds.

BioLife Solutions Stock Performance

NASDAQ BLFS opened at $38.61 on Thursday. BioLife Solutions, Inc. has a 52 week low of $17.86 and a 52 week high of $39.76. The stock’s 50 day moving average price is $37.62 and its two-hundred day moving average price is $28.17. The stock has a market capitalization of $1.89 billion, a price-to-earnings ratio of 33.28 and a beta of 1.82.

BioLife Solutions (NASDAQ:BLFS) last announced its earnings results on Thursday, August 6th. The medical equipment provider reported $0.91 EPS for the quarter, topping the consensus estimate of $0.03 by $0.88. The business had revenue of $28.47 million during the quarter, compared to analysts’ expectations of $27.80 million. BioLife Solutions had a net margin of 53.29% and a return on equity of 2.70%. On average, equities research analysts forecast that BioLife Solutions, Inc. will post 0.03 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on BLFS. Jefferies Financial Group lowered shares of BioLife Solutions from a “buy” rating to a “hold” rating and lifted their price objective for the stock from $30.00 to $31.00 in a research note on Thursday, July 23rd. Weiss Ratings raised shares of BioLife Solutions from a “sell (d-)” rating to a “hold (c)” rating in a report on Tuesday, September 22nd. Lake Street Capital cut shares of BioLife Solutions from a “buy” rating to a “hold” rating and lowered their price objective for the company from $33.00 to $31.00 in a research report on Wednesday, July 22nd. Maxim Group downgraded BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 22nd. Finally, William Blair set a $31.00 price objective on BioLife Solutions in a research note on Thursday, July 23rd. One equities research analyst has rated the stock with a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat.com, BioLife Solutions presently has an average rating of “Hold” and a consensus target price of $31.38.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops and supplies products and services used to preserve, process, store and transport biological materials. Its solutions support the development and manufacture of cell and gene therapies, including products designed to help maintain the viability and functionality of cells, tissues and other biologic materials throughout the bioprocessing workflow.

The company’s portfolio includes preservation media such as CryoStor and HypoThermosol, cell thawing and handling products, and related storage and shipping systems.